Sansure
Sansure is a privately held molecular diagnostics company developing PCR-based in vitro diagnostic products for infectious diseases, HPV screening, blood safety, and respiratory pathogens. It serves hospitals, laboratories, blood banks, and public health agencies globally through seven subsidiary companies and direct distribution.
- Company typePrivate
- Founded2008
- HeadquartersChangshan, China
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Sansure does
Sansure Biotech Inc. (founded 2008, headquartered in Changsha, China) is a privately held in vitro diagnostics company specializing in molecular diagnostics based on real-time PCR (polymerase chain reaction) technology. The company has developed a portfolio of over 500 products spanning six major disease areas: respiratory tract infections, reproductive tract infections, blood-borne infections, gastrointestinal infections, vector-borne diseases, and immunoassays. Its platforms rest on six proprietary core technologies — One-Tube Fast Release Technology, Advanced Magnetic Beads Technology, Fully-Automatic Unified Sample Processing Technology, Multiplex Fluorescent PCR-Amplification Technology, mPOCT (mobile point-of-care testing), and Immunological Technology — which collectively reduce nucleic acid testing time from 5-6 hours to under 30 minutes and enable decentralized testing in resource-limited settings.
The company's commercial offering consists of three integrated layers: (1) automated nucleic acid extraction systems (Natch CS2, Natch CS3 Plus, Natch 48, Natch 16S) using advanced magnetic beads for high-purity sample processing; (2) the iPonatic III portable molecular workstation providing 15-45 minute sample-in-result-out point-of-care testing; and (3) an extensive reagent portfolio covering HPV genotyping (13+2, 15HR, G23, 16/18, 6/11), infectious disease panels (SARS-CoV-2/Flu/RSV, monkeypox, six respiratory pathogens), blood safety screening (HBV/HCV/HIV with CE List A certification), and reproductive tract infections. Sansure operates a B2B sales-led model with direct sales to hospitals, clinical laboratories, blood banks, and government health agencies, augmented by seven wholly-owned subsidiaries (Hongan, Accucise, Hygene, QuantuMDx, inno-train, First Light, Sepset) covering different diagnostic verticals and geographies, plus international distribution partnerships and UNICEF-led public health initiatives in Mongolia, Malaysia, and Sierra Leone. Revenue is generated through one-time sales of reagent kits, hardware sales of instruments and mPOCT devices, and through the recurring consumables revenue that follows the installed instrument base.
Sansure firmographics
Firmographics- Name
- Sansure
- Legal name
- Sansure Biotech Inc.
- Website
- https://sansureglobal.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Sansure is a privately held molecular diagnostics company developing PCR-based in vitro diagnostic products for infectious diseases, HPV screening, blood safety, and respiratory pathogens. It serves hospitals, laboratories, blood banks, and public health agencies globally through seven subsidiary companies and direct distribution.
- Ownership category
- akta.pro rank
Sansure industry classification
Industry- Product category
- In Vitro Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)
- akta.pro secondary industry
- Sample Logistics, Biorepository & IVD Kit Management (Trial Support) (HLAGAEAI)
Keywords
Where Sansure is headquartered
LocationHeadquarters
- HQ city
- Changshan
- HQ country
- China
- HQ region
- Asia
Offices1 record
Markets served
Sansure business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Revenue model
- Diagnostic Reagents: Sale of molecular diagnostic reagent kits for infectious disease detection including HPV, HCV, HBV, HIV, respiratory pathogens, and reproductive tract infections. These are consumable products used with the company's instruments.
- Diagnostic Instruments: Sale and distribution of automated nucleic acid extraction systems (Natch CS2, Natch 48, Natch 16S) and PCR instruments. Instruments provide recurring instrument maintenance and consumables revenue.
- mPOCT Products: Portable molecular workstation (iPonatic III) and associated test kits sold for point-of-care testing in decentralized settings, clinics, and resource-limited environments.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Sansure product offering
Product offeringCore offering
Sansure manufactures and sells molecular diagnostic instruments and reagent kits built on PCR and nucleic acid extraction technologies. Its product ecosystem spans automated extraction systems (Natch CS2, Natch CS3 Plus, Natch 48, Natch 16S), the portable iPonatic point-of-care molecular workstation, and a portfolio of 500+ reagent kits for HPV, HBV, HCV, HIV, respiratory pathogens, monkeypox, and reproductive tract infections. Customers are clinical laboratories, hospitals, blood banks, and public health agencies.
Product overview
Sansure is an in vitro diagnostics company offering a comprehensive molecular diagnostics portfolio centered on real-time PCR technology. The product ecosystem consists of three core pillars: (1) Automated nucleic acid extraction systems (Natch CS2, Natch CS3 Plus, Natch 48, Natch 16S) that use advanced magnetic beads technology for high-purity sample processing; (2) The iPonatic portable molecular workstation series providing point-of-care rapid testing with sample-in-result-out automation in 15-45 minutes; and (3) An extensive reagent portfolio including HPV genotyping kits (S3057E 13+2, S3360E 15HR, S3108E G23, S3019E 16/18, S3017E 6/11), infectious disease panels (SARS-CoV-2/Flu/RSV, Monkeypox, Six Respiratory Pathogens), blood safety screening (HBV/HCV/HIV C004E), and reproductive tract infection tests (CT/UU/NG). The company also provides enabling technology platforms including One-Tube Fast Release Technology, Advanced Magnetic Beads Technology, and Fully-Automatic Unified Sample Processing Technology. All products are designed for compatibility with standard PCR instruments including ABI 7500, QuantStudio 5, and SLAN-96P systems.
Differentiator
Problem solved
Functional benefit
Brands
- iPonatic: Portable Molecular Workstation - mPOCT point-of-care testing device for rapid molecular diagnostics
- Natch
- Sansure eDoc
Products and services
- iPonatic III Portable Molecular Workstation Point-of-care molecular diagnostic device offering fully automated rapid testing with 'sample-in-result-out' capability for clinical laboratories, hospitals, clinics, and resource-limited settings. Delivers results in 15-45 minutes using pre-packaged reagents.
- Natch CS2 Fully Automated Nucleic Acid Extraction System Automated nucleic acid extraction system featuring 3-D magnetic adhesion technology with 117 magnetic racks, anti-contamination design with UV decontamination, and LIS compatibility for laboratory integration. Designed for clinical and hospital laboratories.
- Natch CS3 Plus Fully Automated MDx System Fully integrated molecular diagnostics system combining sample processing, nucleic acid extraction, and detection capabilities in one platform for clinical laboratories.
- Natch 16S Nucleic Acid Extraction System Compact nucleic acid extraction device with 1-16 sample throughput, 10 mixing modes, UV lamp and air filtration for anti-contamination. Features 7-inch touch display with user-friendly interface for smaller laboratories.
- Natch 48 Nucleic Acid Extraction System Automated nucleic acid extraction system designed for medium-to-high throughput laboratories using advanced magnetic beads technology.
- HPV PCR Test Portfolio Portfolio of Human Papillomavirus DNA diagnostic kits detecting multiple high-risk and low-risk HPV genotypes (including types 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68) for cervical cancer screening and HPV genotyping. Used by hospitals and screening programs aligned with WHO cervical cancer elimination strategy.
- Nucleic Acid Test Kit for HBV, HCV, HIV (Type 1+2) (C004E) Blood donor screening kit for nucleic acid qualitative detection of HBV DNA, HCV RNA, HIV-1 RNA, and HIV-2 RNA in pooled or individual samples. CE List A certified. Designed for blood banks and transfusion centers.
- HIV-1 RNA Quantitative Fluorescence Diagnostic Kit (S3046E) Quantitative detection of HIV-1 virus RNA in human EDTA plasma with sensitivity of 25 IU/mL for clinical monitoring of HIV patients. CE-certified.
- HCV RNA Detection Kit (HCV Ultra) Hepatitis C virus RNA detection reagents with qualitative sensitivity of 10 IU/mL and quantitative sensitivity of 12 IU/mL for HCV screening and treatment monitoring in clinical settings.
- HBV DNA Quantitative Diagnostic Kit (HBV Ultra) Hepatitis B virus DNA quantitative fluorescence diagnostic kit for quantification of HBV DNA in human serum using advanced magnetic beads technology. Used by hospitals and clinical laboratories.
- SARS-CoV-2/Flu/RSV Combination Kit (S3148E) Multiplex nucleic acid kit for simultaneous detection and differentiation of SARS-CoV-2, influenza, and RSV. Provides results in 36 minutes when paired with iPonatic for clinical and point-of-care use.
- Six Respiratory Pathogens Multiplex Nucleic Acid Diagnostic Kit (S3310E) Multiplex PCR kit detecting six respiratory pathogens including Legionella pneumophila and Haemophilus influenzae with sensitivity of 340 CFU/ml for clinical infectious disease diagnostics.
- S3352E MPXV Monkeypox Virus Nucleic Acid Diagnostic Kit Monkeypox virus nucleic acid diagnostic kit with sensitivity of 200 copies/ml using one-tube fast-release technology. Test time less than 30 minutes.
- CT/UU/NG DNA Diagnostic Kit (S3050E) Simultaneous detection kit for Chlamydia trachomatis, Neisseria gonorrhoeae, and Ureaplasma urealyticum using real-time fluorescence quantitative PCR for early RTI diagnosis in clinical and reproductive health settings.
- Herpes Simplex Virus Type 2 DNA Diagnostic Kit (S3002E) DNA fluorescence diagnostic kit for detection of HSV-2 DNA in samples for early diagnosis of herpes infection in clinical and reproductive health settings.
- Respiratory Adenovirus DNA Diagnostic Kit DNA diagnostic kit for detection of respiratory adenovirus with lowest limit of detection of 200 copies/ml. Compatible with common PCR instruments including ABI 7500, QuantStudio 5, and SLAN-96P systems.
- DNA/RNA Extraction Reagents Sample preparation reagents for extraction and purification of DNA and RNA from various clinical specimens for molecular diagnostics workflows.
Companies that use Sansure
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
Sansure technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability2 records
Feature6 records
Sansure partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core.
- UNICEF MongoliacoreStrategic partnership to safeguard maternal and child health in Mongolia. Sansure collaborates with UNICEF Mongolia on public health initiatives, providing diagnostic solutions and support for health programs targeting maternal and child health outcomes.
- HongancoreSubsidiary company of Sansure focused on specific diagnostic solutions, operating under the Sansure group corporate structure.
- AccucisecoreSubsidiary company of Sansure, operating as part of the Sansure group of companies to expand diagnostic product offerings and market reach.
- HygenecoreSubsidiary company of Sansure focused on hygiene and diagnostics-related products, part of the Sansure corporate ecosystem.
- QuantuMDxcoreSubsidiary company of Sansure operating within the Sansure group, contributing to the collective diagnostic portfolio.
- inno-traincoreSubsidiary company of Sansure, part of the Sansure group network of diagnostic companies.
- First LightcoreSubsidiary company of Sansure operating as part of the Sansure group, focused on specific diagnostic applications.
- SepsetcoreSubsidiary company of Sansure included in the Sansure group of companies for expanded diagnostic capabilities.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Sansure competitors and assessment
Company assessmentDirect peers
- Hologic: Direct competitor in women's health molecular diagnostics, including HPV testing (Aptima) and Panther automated systems. Hologic's high-throughput HPV screening reagents compete directly with Sansure's HPV 13+2, 15HR, and G23 genotyping kits.
- Daan Gene: Chinese IVD company with strong nucleic acid test (NAT) portfolio for HBV, HCV, HIV blood screening, and HPV. Daan Gene is a direct Chinese competitor in blood safety screening and HPV, the same core categories as Sansure.
- Qiagen: Direct peer in nucleic acid extraction and sample preparation technologies (QIAcube, QIAsymphony), plus molecular diagnostic kits for HPV and infectious diseases. Qiagen's magnetic-bead extraction technology directly competes with Sansure's Advanced Magnetic Beads platform.
- Autobio Diagnostics: Chinese-domestic IVD company with overlapping products in chemiluminescence immunoassays, microbiology, and molecular diagnostics. Autobio is the most direct Chinese-listed competitor to Sansure's broader diagnostics portfolio.
- Seegene: Direct competitor in multiplex PCR-based molecular diagnostics, particularly for syndromic infectious disease panels. Seegene's Allplex assays compete with Sansure's multiplex respiratory pathogen and CT/UU/NG reproductive infection kits.
- Snibe Diagnostics: Shenzhen-headquartered IVD company with chemiluminescence immunoassay and molecular diagnostic products. Snibe is a comparable Chinese IVD peer with international expansion (CE-marked, exported globally) overlapping Sansure's strategy.
- Cepheid (Danaher): Direct competitor in PCR-based molecular diagnostics, particularly the GeneXpert system for point-of-care and clinical lab nucleic acid testing. Cepheid's cartridge-based PCR platform competes directly with Sansure's iPonatic mPOCT station and Natch extraction systems.
Broad incumbents
- Roche Diagnostics: Broad incumbent in molecular diagnostics with cobas systems and a comprehensive infectious disease, HPV, and blood screening menu. Roche's entrenched installed base in hospital labs sets the competitive benchmark Sansure seeks to disrupt.
- Abbott Molecular: Broad incumbent with m2000 and Alinity m systems for molecular diagnostics, covering HPV, HIV, HCV, and HBV. Abbott's global blood bank and clinical lab presence competes with Sansure's C004E blood screening kit and infectious disease portfolio.
- bioMérieux (BioFire): Broad incumbent with the BioFire FilmArray syndromic PCR panels for respiratory, gastrointestinal, and bloodstream infections. BioFire's point-of-care syndromic testing model overlaps with Sansure's iPonatic mPOCT strategy in decentralized settings.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Sansure social profiles
Digital presenceSansure compliance and trust
Trust signalCompliance3 records
Sansure financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sansure leadership team
Management profileNumber of profiles
Profiles1 record
Sansure subsidiaries and ownership
Company hierarchySubsidiaries7 records
Sansure funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sansure M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sansure
What does Sansure do?
Sansure manufactures and sells molecular diagnostic instruments and reagent kits built on PCR and nucleic acid extraction technologies. Its product ecosystem spans automated extraction systems (Natch CS2, Natch CS3 Plus, Natch 48, Natch 16S), the portable iPonatic point-of-care molecular workstation, and a portfolio of 500+ reagent kits for HPV, HBV, HCV, HIV, respiratory pathogens, monkeypox, and reproductive tract infections. Customers are clinical laboratories, hospitals, blood banks, and public health agencies.
Is Sansure a public or private company?
Sansure is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Sansure founded?
Sansure was founded in 2008. It employs 501 to 1,000 people.
Where is Sansure based?
Sansure is headquartered in Changshan, China, in the Asia region.
How does Sansure make money?
Three revenue lines are on record. Diagnostic Reagents are the primary driver. The others are diagnostic Instruments and mPOCT Products.
Who are Sansure's main competitors?
Direct peers on record are Hologic, Daan Gene, Qiagen, Autobio Diagnostics, Seegene, Snibe Diagnostics and Cepheid (Danaher). Broad incumbents are Roche Diagnostics, Abbott Molecular and bioMérieux (BioFire).
Does Sansure have an API?
No public API is recorded for Sansure.
What industry is Sansure in?
Sansure's product category is In Vitro Diagnostics. Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes), with a secondary code of HLAGAEAI, Sample Logistics, Biorepository & IVD Kit Management (Trial Support). Its NAICS code is 325413 and its SIC code is 2835.